Cancer NetworkOriginal article
<![CDATA[Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma]]>
Phase 3negativeSurVaxMTemozolomideNegative
AI Analysis
Summary
SurVaxM cancer vaccine combined with temozolomide failed to achieve statistical significance for overall survival in the Phase 3 SURVIVE trial for newly diagnosed glioblastoma patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Missed statistical significance for overall survival in newly diagnosed glioblastoma patients
Importance:7/10
Sentiment:
-0.85
glioblastomacancer vaccineclinical trial failurePhase 3SURVIVE trial
Read the original article
Published by Cancer Network on October 7, 2026 9:00 PM